By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on Immunology. According to news reporting originating from Nagoya, Japan, by NewsRx correspondents, research stated, "Technologies for the transfection of antigen-encoding genes into the dendritic cells, and subsequent immune-activation are both prerequisites for a successful DNA vaccine. We herein report on the density-dependent enhancement of transgene expression by the simple modification by stearyl-conjugated KALA, an alpha-helical peptide (STR-KALA), onto a lipid envelope-type nanoparticle (the R8-MEND, an octaarginine-modified multifunctional envelope-type nano device)."
Our news editors obtained a quote from the research from Nagoya University, "The enhanced transgene expression in the KALA-modified R8-MEND (R8/KALA-MEND) cannot be explained by cellular uptake and nuclear delivery efficacy. Thus, the post-nuclear delivery process (i.e. transcription), but not intracellular trafficking processes attributed the enhanced transfection efficacy. Microarray analyses revealed that transfection with the R8/KALA-MEND resulted in a greater perturbation in host genes expression in comparison with the R8-MEND and that this effect was time-dependent. Further pathway analyses in the category of transcription-related genes and a gene ontology analysis indicated that the R8/KALA-MEND stimulated the expression of transcription factors that are closely related to immune-activation (i.e. NF-kB and STAT). Inhibition of the transfection efficacy by blockage of the STAT pathways revealed that the enhanced transcription activity is the result of immune-stimulation."
According to the news editors, the research concluded: "Collectively, the R8/KALA-MEND mounts a 'switch-on' function that triggers signal transduction forward to the immune-stimulation analogous to an adjuvant, and consequently elicits active transcription."
For more information on this research see: A DNA microarray-based analysis of immune-stimulatory and transcriptional responses of dendritic cells to KALA-modified nanoparticles. Biomaterials, 2013;34(35):8979-8990. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
The news editors report that additional information may be obtained by contacting H. Akita, Nagoya University, Dept. of Appl Chem, Grad Sch Engn, Nagoya, Aichi 46401, Japan. Additional authors for this research include S. Ishii, N. Miura, S.M. Shaheen, Y. Hayashi, T. Nakamura, N. Kaji, Y. Baba and H. Harashima (see also Immunology).
Keywords for this news article include: Asia, Antigen-Presenting Cells, Japan, Nagoya, Immunology, DNA Research, DNA Vaccines, Nanoparticle, Nanotechnology, Dendritic Cells, Synthetic Vaccines, Emerging Technologies, Mononuclear Phagocyte System
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC